Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1358 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Innovative Molecules–Life Sciences Partners: investment, 202106 financing round Series A totalling €20m incl lead investor LSP 2021-06-07
Innovative Molecules–SEVERAL: investment, 202106 financing round Series A €20m led by LSP 2021-06-07
Amyl Therapeutics–Huntsworth: public relations, 202106 service existent by Citigate Dewe Rogerson 2021-06-03
Amyl Therapeutics–Mérieux: investment, 202106 financing round Series A totalling €8.6m incl co-investor Mérieux Participations 2021-06-03
Amyl Therapeutics–Noshaq: investment, 202106 financing round Series A totalling €8.6m incl lead investor Noshaq 2021-06-03
Amyl Therapeutics–Sambrinvest: investment, 202106 financing round Series A totalling €8.6m incl co-investor Sambrinvest 2021-06-03
Amyl Therapeutics–SEVERAL: investment, 202106 financing round Series A €8.6m led by Noshaq 2021-06-03
Amyl Therapeutics–Wallonia (govt): grant/credit?, 202106 non-dilutive funding €9.7m from DG06 2021-06-03
ImaginAb–Norgine: investment, 202106 financing round totalling $12.8m incl new + co-investor Norgine Ventures 2021-06-03
ImaginAb–SEVERAL: investment, 202106 financing round $12.8m co-led by existing investors Adage Capital + Cycad Group 2021-06-03
Gilde Investment–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media contact for Gilde Healthcare 2021-06-02
Origin.bio–Inventures: investment, 202105 financing round totalling $15m incl new + co-investor Inventures 2021-05-26
Ziphius Vaccines–OTHER: credit, 202105 convertible loan €5m 2021-05-25
Ziphius Vaccines–PERSON: investment, 202105 financing round Series A totalling €24.3m incl cornerstone investor Annie Vereecken 2021-05-25
Ziphius Vaccines–SEVERAL: investment, 202105 financing round Series A €24.3m incl Belgian Family Offices 2021-05-25
Numab–Forbion: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Forbion Growth Opportunities Fund 2021-05-20
Numab–SEVERAL: investment, 202105 financing round Series C CHF100m co-led by new investors Novo Holdings + HBM Partners 2021-05-20
Hummingbird Bioscience–Droia Ventures: investment, 202105 financing round Series C totalling $125m incl new + co-investor Droia Ventures 2021-05-18
Hummingbird Bioscience–SEVERAL: investment, 202105 financing round Series C $125m led by Novo Holdings 2021-05-18
Accent Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Arcus Biosciences–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Aura Biosciences–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Cyteir Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Dutch DNA Biotech–Ginkgo Bioworks: investment, 202105– acquisition in cash + shares ANNOUNCED 2021-05-17
Highlight Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Montis Biosciences–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
PACT Pharma–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
QurAlis–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Volastra Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Droia Ventures–SEVERAL: investment, 202105 final close €220m of Droia Genetic Disease Fund 2021-05-11
Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital 2021-04-29
Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe 2021-04-28
Molecular Partners–SEVERAL: investment, 202104– US IPO at Nasdaq FILED 2021-04-23
Anavo Therapeutics–ABP (NL): investment, 202104 seed financing round totalling €20m incl co-lead investor Inkef Capital 2021-04-22
Anavo Therapeutics–Bioqube Ventures: investment, 202104 seed financing round totalling €20m incl co-investor Bioqube Ventures 2021-04-22
Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall 2021-04-22
Anavo Therapeutics–Merck (DE): investment, 202104 seed financing round totalling €20m incl co-lead investor M Ventures 2021-04-22
Anavo Therapeutics–Otsuka: investment, 202104 seed financing round totalling €20m incl co-investor Taiho Ventures 2021-04-22
Anavo Therapeutics–SEVERAL: investment, 202104 seed financing round €20m led by M Ventures + Inkef Capital 2021-04-22
Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I 2021-04-20
Forbion–Wealth Management Partners: investment, 202104 final closing at €360m of Forbion Growth Opportunities Fund I incl investor WMP 2021-04-20
Rinri Therapeutics–BioCity (GB): investment, 202104 financing round totalling £10m incl existing investor BioCity 2021-04-20
Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund 2021-04-20
Rinri Therapeutics–UCB: investment, 202104 financing round totalling £10m incl existing investor UCB Ventures 2021-04-20
Lumicks–Farallon Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Farallon Capital 2021-04-16
Lumicks–Gilde Investment: investment, 202104 financing round Series D totalling $93m preferred shares incl existing + co investor Gilde HC 2021-04-16
Lumicks–Irving Investors: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Irving Investors 2021-04-16
Lumicks–Lauxera Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Lauxera Capital 2021-04-16
Lumicks–Parian Global Management: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Parian Global Mgt 2021-04-16
Lumicks–Pura Vida Investments: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Pura Vida 2021-04-16
Lumicks–SEVERAL: investment, 202104 financing round Series D $93m preferred shares led by Farallon Capital + Lauxera Capital 2021-04-16
Lumicks–Softbank: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Softbank Vision 2 2021-04-16
Lumicks–T Rowe Price: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor funds managed by T Rowe Price 2021-04-16
Gyroscope Therapeutics–Forbion: investment, 202103 financing round Series C totalling $148m incl lead investor Forbion Growth I 2021-03-26
Gyroscope Therapeutics–SEVERAL: investment, 202103 financing round Series C $148m led by Forbion Growth I 2021-03-26
Leyden Laboratories–Alphabet: investment, 202103 financing round Series A totalling €40m incl lead investor GV 2021-03-25
Leyden Laboratories–Brook Byers: investment, 202103 financing round Series A totalling €40m incl co-investor Brook Byers 2021-03-25
Leyden Laboratories–Casdin Capital: investment, 202103 financing round Series A totalling €40m incl co-investor Casdin Capital 2021-03-25
Leyden Laboratories–F-Prime: investment, 202103 financing round Series A totalling €40m incl co-investor F-Prime 2021-03-25
Leyden Laboratories–LifeSci: public relations, 202103 supply service existent by LifeSci Communications 2021-03-25
Leyden Laboratories–SEVERAL: investment, 202103 financing round Series A €40m led by GV 2021-03-25
Meatable–Agronomics: investment, 202103 financing round Series A totalling $47m incl existing investor Agronomics 2021-03-23
Meatable–BlueYard Capital: investment, 202103 financing round Series A totalling $47m incl existing investor BlueYard Capital 2021-03-23
Meatable–DSM: investment, 202103 financing round Series A totalling $47m incl new investor DSM Venturing 2021-03-23
Meatable–Humboldt Fund: investment, 202103 financing round Series A totalling $47m incl existing investor Humboldt Fund 2021-03-23
Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl existing investor Taavet Hinrikus 2021-03-23
Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl new investors Rick Klausner + Jeffrey Leiden 2021-03-23
Meatable–Section 32: investment, 202103 financing round Series A totalling $47m incl new investor Section 32 2021-03-23
Meatable–SEVERAL: investment, 202103 financing round Series A $47m from existing + new investors 2021-03-23
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare 2021-03-17
ExeVir Bio–Noshaq: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Noshaq 2021-03-16
ExeVir Bio–Sambrinvest: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Sambrinvest 2021-03-16
ExeVir Bio–SEVERAL: investment, 202103 financing round Series A extension by €19m + closing at total of €42m 2021-03-16
ExeVir Bio–UCLouvain: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Vives IUF 2021-03-16
ExeVir Bio–Wallonia (govt): investment, 202103 financing round Series A extension totalling €19m incl new + co-investor SRIW 2021-03-16
AgomAb Therapeutics–Advent France Biotechnology: investment, 202103 financing round Series B totalling $74m incl existing + co-investor AFB 2021-03-10
AgomAb Therapeutics–Andera Partners: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Amdera Partners 2021-03-10
AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF 2021-03-10
AgomAb Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series B totalling $74m incl new + co-investor Cormorant 2021-03-10
AgomAb Therapeutics–Omnes Capital: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Omnes Capital 2021-03-10
AgomAb Therapeutics–Pontifax: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Pontifax 2021-03-10
AgomAb Therapeutics–Redmile Group: investment, 202103 financing round Series B totalling $74m incl new + lead investor Redmile Group 2021-03-10
AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group 2021-03-10
AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications 2021-03-10
AgomAb Therapeutics–V-Bio Ventures: investment, 202103 financing round Series B totalling $74m incl existing + co-investor V-Bio Ventures 2021-03-10
Diagenode–Hologic: investment, 202103 acquisition €130m of Diagenode by Hologic 2021-03-01
Oxular–Forbion: investment, 202103 financing round totalling £27m incl new + lead investor Forbion 2021-03-01
Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion 2021-03-01
Delphi Genetics–Achelous Partners: financial services, 202102 supply service M&A adviser for sale of Delphi Genetics to Catalent 2021-02-23
Delphi Genetics–Catalent: investment, 202102– acquisition 100% valuing Delphi Genetics at $55m 2021-02-23
Delphi Genetics–Osborne Clarke: legal services, 202102 supply service Osborne Clarke Brussels legal adviser to Delphi Genetics on sale Catalent 2021-02-23
Pan Cancer T–Netherlands (govt): grant, 202102 Health~Holland grant for public-private-partnership with Erasmus Medical Center 2021-02-08
Pan Cancer T–SEVERAL: investment, 202102 seed financing round from Swanbridge Capital + Van Herk Ventures 2021-02-08
Pan Cancer T–Swanbridge Capital: investment, 202102 seed financing round incl investor Swanbridge Capital 2021-02-08
Pan Cancer T–Van Herk: investment, 202102 seed financing round incl investor Van Herk Ventures 2021-02-08
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets 2021-02-04
V-Bio Ventures–SEVERAL: investment, 202102 first closing €78m capital commitments for new V-Bio Ventures Fund 2 2021-02-04
GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA 2021-01-26
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences 2021-01-26
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share 2021-01-25
1 2 3 4 5 6 7 8 9 10 11 12 13 14  next pagenext page



Advertisement

Picture [iito] Plain Stupid Simple 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

» top